Categories: Market Research

Hepatitis Diagnostic Tests Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Hepatitis Diagnostic Tests Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Hepatitis Diagnostic Tests Market:

https://www.thebusinessresearchcompany.com/report/hepatitis-diagnostic-tests-global-market-report

According to The Business Research Company’s Hepatitis Diagnostic Tests Global Market Report 2024, The hepatitis diagnostic tests market size has grown strongly in recent years. It will grow from $4.35 billion in 2023 to $4.64 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to globalization of healthcare, government initiatives, high disease burden, increased blood safety measures, public health campaigns..

The hepatitis diagnostic tests market size is expected to see strong growth in the next few years. It will grow to $5.85 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to global health security concerns, population growth and urbanization, tailored testing strategies, emphasis on elimination programs, increasing healthcare spending.. Major trends in the forecast period include advancements in testing technologies, multiplex testing for different hepatitis viruses, integration of molecular diagnostics, digital health solutions, strategic collaborations and partnerships..

The rising number of blood transfusions and donations is expected to propel the growth of the hepatitis diagnostic test market going forward. Blood transfusions and blood donation are interconnected processes in which individuals willingly provide their blood, which is collected, tested, and subsequently administered to patients who require additional blood components to treat medical conditions or replace lost blood due to surgeries, accidents, or illnesses. Hepatitis diagnostic tests are used to thoroughly screen blood before donation or transfusion to assure the safety of patients. For instance, in December 2021, according to NHS Blood and Transplant (NHSBT), a UK-based organization responsible for blood collection, testing, organ retrieval, and transplantation allocation, whole blood donations in the UK increased to 1,719,630 by 963,145 donors in 2021, compared to 1,649,057 by 933,705 donors in 2020. Therefore, the rising number of blood transfusions and donations drives the hepatitis diagnostic test market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13153&type=smp

The hepatitis diagnostic tests market covered in this report is segmented –

1) By Test Type: Blood Tests, Imaging Tests, Liver Biopsy

2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDTs), Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Test (INAAT), Other Technologies

3) By End User: Hospitals, Diagnostic Laboratories, Blood Bank, Other End Users

Major companies operating in the hepatitis diagnostic test market focus on developing innovative automated immunoassays, such as Elecsys HCV Duo, to provide reliable customer service. Elecsys HCV Duo Automated immunoassays are laboratory techniques that use automation systems and specialized instruments to carry out all phases of the immunoassay procedure, such as sample handling, reagent mixing, incubation, detection, and result calculation. For instance, in July 2023, Roche Diagnostics India, an India-based biotechnology research company, launched Elecsys HCV Duo. It is India’s first commercially available fully automated immunoassay that enables simultaneous and independent assessment of the hepatitis C virus (HCV) antigen and antibody levels from a single human plasma or serum sample. This also provides single specimen testing and streamlines the diagnostic algorithm, which reduces the number of visits required to take further tests and can lessen the burden of testing on the healthcare system.

The hepatitis diagnostic tests market report table of contents includes: